Impact Factor : 0.548
Georgios Mikellides* and Marianna Tantele
Received: August 08, 2018; Published: August 14, 2018
*Corresponding author: Georgios Mikellides, Honorary Assistant Professor University of Nicosia, Consultant Psychiatrist at Cyprus rTMS
The use of repetitive transcranial magnetic stimulation has grown over the last ten years since the FDA approval in 2008 and has been also included in NICE UK as an optional treatment  and it is likely to continue to grow in terms of its use as it has been showing the following promising findings: good results in a variety of neuropsychiatric disorders such as anxiety , obsessive compulsive disorder , auditory hallucinations , PTSD , tinnitus , migraine , post-stroke rehabilitation  etc. It also provides a neuroprotective mechanism  which may enhance cognitive function.
We would like to present a 52 year old lady with a history of recurrent depressive disorder, with the current episode lasting over two years. She had a history of recurrent depressive disorder since she was 17 years old. Her current presentation was with decreased sleep, decreased appetite, lack of concentration, lack of energy, low mood and anhedonia as she could not enjoy anything in her life anymore. She was partially functioning socially and with keeping up a part time job. She was on Lamictal (Lamotrigine) 50 mg BD, Efexor XR (Venlafaxine) 150mg daily, Seroquel (Quetiapine) 50mg nocte and Wellbultrin (Buproprion) 150mg daily when she came to our clinic. She was previously tried on higher doses of Efexor XR (Venlafaxine) with no response from her clinical history.
Also 6 months prior to attending to our clinic she received a total of 8 sessions of ECT twice weekly with some improvement in her mental state at the time but not with a sustainable effect and did not lead to a full recovery. She had a medication review and Lamotrigine was stopped to have a better effect with rTMS. Subsequently we did start a 5 times per week rTMS course over 6 weeks with a magpro (Magventure) stimulator, theta burst pulses were given for 3 minutes in each session, on the left DLPFC, a total of thirty sessions. The patient went into a full recovery of her depressive episode one week post treatment completion. We also stopped Buproprion, Quetiapine and during treatment we also increase Venlafaxine XR to 150mg BD. She did not present with any side effects from the rTMS therapy. She was also reviewed a month post treatment and the effect was sustained and decided to have a monthly maintenance session with rTMS.
Our case suggests that rTMS can be an effective treatment option in treatment resistant depression even in patients that they have been previously tried on ECT and did not recover or sufficiently responded. Also, the recommendation could be that rTMS could be used as a first line treatment in patients with depression as it presents with less side effects as if its to be compared to medications or ECT and its an effective and safe treatment above all.